Slide 1: Making improvements in life possible
Making improvements in life possible Investor introduction September 2023
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. S
Slide 3: We help advance science and improve outcomes
We help advance science and improve outcomes Our Mission Enabling access to valuable insights from molecular research to clinical healthcare Our Vision Making improvements in life possible Investor Introduction 3
Slide 4: QIAGEN at a glance
QIAGEN at a glance A global company with scale ~45% $2.1 Americas billion Sales ~35% (2022 (2022) EMEA sales) ~20% Asia-Pacific / Japan Highly recurring revenues Balanced customer markets ~6,200 employees known as QIAGENers ~ 88% 12% ~ ~ 50% 50% ~ Consumables and related revenues Instruments Molecul
Slide 5: QIAGEN solutions are used across the world
QIAGEN solutions are used across the world by researchers - from young scientists to Nobel laureates - and clinical testing labs Investor Introduction 5
Slide 6: More than 3 billion samples have been processed
More than 3 billion samples have been processed using QIAGEN sample preparation kits Dr. Darren Chooneea Research Scientist, London Natural History Museum Uses QIAGEN’s PowerSoil Pro Kit to explore the evolution of microorganisms as they adapted to changing environmental conditions and identify the
Slide 7: QIAGEN's innovative instrument portfolio
QIAGEN’s innovative instrument portfolio tackles a variety of molecular applications Dr. Johanna Andersson-Assarsson University of Gothenburg Uses QIAGEN’s QIAcuity digital PCR platform to identify gene variations that could help in the development of new therapies Investor Introduction 7
Slide 8: More than 100 million patients have been screened
More than 100 million patients have been screened with QIAGEN’s latent TB test Dr. Kiyoyasu Fukushima Japan Red Cross Nagasaki Genbaku Isahaya Hospital Employs QuantiFERON TB Plus for latent tuberculosis detection to ultimately reduce Japan‘s high infection rate Investor Introduction 8
Slide 9: QIAGEN is developing companion diagnostics
QIAGEN is developing companion diagnostics with over 30 Pharma companies Dr. Philippe Taniere Consultant histopathologist Queen Elizabeth Hospital Birmingham Relies on QIAGEN’s standardized, regulatory-approved tests to break the cellular code of cancer and find the right treatment for each patient
Slide 10: More than 4 million samples have been processed
More than 4 million samples have been processed with QIAGEN’s NGS kits Asha Palat and Brandon Mistretta University of Houston’s Department of Biology and Biochemistry Use QIAGEN’s QIAseq FastSelect RNA Removal Kits with next-generation sequencing (NGS) to develop more effective and more humane cance
Slide 11: Every 10 seconds a crime scene sample is analyzed
Every 10 seconds a crime scene sample is analyzed with QIAGEN kits Rachel Oefelein Chief Scientific Officer at DNA Labs International Helping to bring closure to victims and their families by using QIAGEN’s forensic genetic genealogy tools to enable identification of assailants by matching genetic r
Slide 12: QIAGEN products are known for the highest quality
QIAGEN products are known for the highest quality Investing ~9-10% of sales in R&D and best-in-class manufacturing Investor Introduction 12
Slide 13: Providing Sample to Insight solutions
Providing Sample to Insight solutions to uncover molecular insights Sample technologies Assay technologies Discovery research Advancing understanding of life Pharma Faster and better drug R&D Clinical diagnostics Sample to Insight solutions Accurate disease diagnosis Automation systems Bioinformatic
Slide 14: Life Sciences: Working to enable scientific advancements
Life Sciences: Working to enable scientific advancements QIAGEN value Academic research 2022 sales ~$1 billion Pharma development Recognized innovator supporting scientific breakthroughs Able to translate innovations Applied testing into commercial products ~$5 billion addressable market Selected QI
Slide 15: Molecular Diagnostics: Helping to improve outcomes in healthcare
Molecular Diagnostics: Helping to improve outcomes in healthcare QIAGEN value Immune response 2022 sales ~$1.1 billion Infectious diseases Addressing testing areas with high or growing demand Strong automation portfolio Oncology with multi-year assay menu expansion underway ~$6 billion addressable m
Slide 16: Our strategy: Leveraging a strong core portfolio
Our strategy: Leveraging a strong core portfolio to drive key pillars Expanding on solid leadership Early commercialization phases with strong growth potential Sample QuantiFERON QIAstat-Dx NeuMoDx QIAcuity technologies Leading immune Syndromic testing with Differentiated microfluidic Novel micropla
Slide 17: Sample Technologies: Building on solid leadership
Sample Technologies: Building on solid leadership Most comprehensive portfolio Ongoing automation upgrade program >300 consumables kits and range of automation systems >20,000 instrument placements in the market QIAcube Connect Tissue Stool Upgrade launched 2021 Cells Saliva >14,000 cumulative place
Slide 18: QuantiFERON TB: Best-in-class test for latent TB
QuantiFERON TB: Best-in-class test for latent TB Enabling hands-free processing of QFT-TB Gold Plus ~25-30% latent TB testing has been converted from skin test QFT-TB Gold Plus High performing Excellent Wide menu assay automation Embedded in QFT TB Gold Plus DiaSorin, DiaSorin menu • Can be fully au
Slide 19: QIAstat-Dx: Reliable near-patient syndromic testing
QIAstat-Dx: Reliable near-patient syndromic testing Unrivaled ease-of-use More than a “yes/no” No sample preparation answer for deeper QIAstat-Dx test menu CE-IVD FDA clinical insights Gastrointestinal Respiratory SARS CoV-2 1 2 3 4 Transfer Press Run Insert View results sample to and scan cartridge
Slide 20: NeuMoDx: New generation of integrated PCR testing
NeuMoDx: New generation of integrated PCR testing >300 NeuMoDx CE-IVD test menu Offering the ease of clinical chemistry for cumulative molecular testing placements (1) HBV Blood-borne HCV viruses HIV CMV Easier Faster More versatile EBV 2.0 Simple three-step First results in ~1 hour Laboratory-devel
Slide 21: QIAcuity: Enabling wide access to digital PCR
QIAcuity: Enabling wide access to digital PCR Integrated instrument offering sample-in, result-out ease >1,300 cumulative placements (1) Scalable Easier Faster Greater Fully automated Over twice as fast flexibility workflow time-to-result QIAcuity One QIAcuity Four QIAcuity Eight Differentiated nano
Slide 22: We employ ~6,200 passionate QIAGENers
We employ ~6,200 passionate QIAGENers around the world from diverse backgrounds and locations Investor Introduction 22
Slide 23: Strong global presence in developed and emerging markets
Strong global presence in developed and emerging markets >30 Our global Direct sales in and regional headquarters: Venlo Netherlands Germantown Global HQ countries Maryland Americas HQ Hilden Germany EMEA HQ Shanghai China HQ Singapore >170 Shipping product to Asia-Pacific HQ countries Investor Intr
Slide 24: Outlook: Q3 and FY 2023
Outlook: Q3 and FY 2023 Q3 2023 outlook Updated FY 2023 outlook (As of August 8, 2023) Net sales ≥ $465 million CER ≥ $1.97 billion CER Anticipated currency impact Up to ~1 percentage point benefit Neutral FX impact (Prior ≥ $2.05 billion CER) ≥ $2.07 CER Adjusted diluted EPS ≥ $0.48 CER Neutral FX
Slide 25: Maintaining financial flexibility with appropriate leverage
Maintaining financial flexibility with appropriate leverage Structure as of December 31, 2022 Maturities of debt instruments (In $ millions) $1.91 billion $1.42 billion Cash and short-term Convertible Bonds Schuldschein Convertible investments Bonds 117 2023 2024 2027 601 613 101 113 400 $492 millio
Slide 26: Capital allocation: Strong balance sheet to create greater value
Capital allocation: Strong balance sheet to create greater value Investing in growth Healthy cash flow and leverage ratio trends $ Expanding test menus and millions manufacturing capacity, 800 1.6x especially in the five pillars 700 1.5x 1.4x 600 Enhance value with M&A 500 Ongoing disciplined approa
Slide 27: Why invest: Well-diversified business spanning attractive markets
Why invest: Well-diversified business spanning attractive markets Diversified Broad Highly customer base geographic reach recurring revenues Well-balanced leadership in ~6,200 QIAGENers ensuring Growing installed base Life Sciences and access to attractive markets with generating demand for Molecula
Slide 28: Appendix
Appendix |
Slide 29: Q3 and FY 2023: Outlook and assumptions
Q3 and FY 2023: Outlook and assumptions (As of August 8, 2023) Q3 2023 outlook Updated FY 2023 outlook >$1.97 billion CER Net sales >$465 million CER (Prior > $2.05 billion CER) Anticipated currency impact(1) Up to +~1 ppt Neutral FX impact >$2.07 CER Adjusted diluted EPS(2) >$0.48 CER (Prior > $2.1
Slide 30: Q2 2023: Consolidated Statements of Income
Q2 2023: Consolidated Statements of Income (unaudited) Three months ended Three months ended (In $ thousands, except share data) June 30, 2023 June 30, 2022 Net sales 494,857 515,512 Cost of sales: Cost of sales 166,637 169,381 Acquisition-related intangible amortization 16,068 15,113 Total cost of
Slide 31: H1 2023: Consolidated Statements of Income
H1 2023: Consolidated Statements of Income (unaudited) Six months ended Six months ended (In $ thousands, except share data) June 30, 2023 June 30, 2022 Net sales 980,255 1,143,903 Cost of sales: Cost of sales 328,543 367,499 Acquisition-related intangible amortization 32,084 30,416 Total cost of sa
Slide 32: 2023: Quarterly sales by product group
2023: Quarterly sales by product group (In $ millions at actual rates / Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 173 -35% 32% 165 -7% -7% 338 -24% -22% Diagnostic solutions(1) 1
Slide 33: 2023: Sales by non-COVID and COVID-19 product groups
2023: Sales by non-COVID and COVID-19 product groups (In $ millions at actual rates / Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Non-COVID product groups 434 8% 12% 457 8% 9% 891 8% 10% COVID-19 prod
Slide 34: 2023: Quarterly sales by product type, customer class and region
2023: Quarterly sales by product type, customer class and region (In $ millions at actual rates / Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 431 -23% -21% 434 -4%
Slide 35: Q2 and H1 2023: Reconciliation to adjusted results
Q2 and H1 2023: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pretax Income Tax Net Diluted sales profit income income tax rate income EPS Second quarter 2023 Reported results 494.9 312.1 105.4 102.3 (21.5) 21% 80.8 0.35 Adjustments Business integrati
Slide 36: Q2 and H1 2023: Footnotes for reconciliation to adjusted results
Q2 and H1 2023: Footnotes for reconciliation to adjusted results (unaudited) a) Results for 2023 include costs for acquisition projects, including the acquisition of Verogen Inc. completed on January 4, 2023. Results for 2022 include acquisition projects including continued integration activities at
Slide 37: 2023: Quarterly income statement summary
2023: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 Net sales 485.4 494.9 980.3 Net sales (CER) 501.6 497.4 999.0 Gross profit 307.5 312.1 619.6 Gross profit margin 63.3% 63.1% 63.2% Adjusted gross profit 326
Slide 38: Consolidated Balance Sheets
Consolidated Balance Sheets June 30, December 31, June 30, December 31, (In $ thousands, except par value) 2023 2022 (In $ thousands, except par value) 2023 2022 Assets (unaudited) Liabilities and Equity (unaudited) Cash and cash equivalents 609,549 730,669 Current portion of long-term debt 500,149
Slide 39: Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows (unaudited) Six months ended June 30, June 30, Six months ended June 30, June 30, (In $ thousands) 2023 2022 (In $ thousands) 2023 2022 Cash flows from operating activities: Cash flows from financing activities: Net income 165,821 251,973 Proceeds from issuance
Slide 40: Q2 and H1 2023: Currency impact
Q2 and H1 2023: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q2 2023 0 U.S. dollar 263.8 263.8 53% 0.0 Euro 100.8 98.6 20% -2.2 British pound 20.4 20.5 4% 0.1 Japanese yen 9.7 10.3 2% 0.6 Other currencies 100.1 104.2
Slide 41: Your contacts
Your contacts Phoebe Loh Senior Director Calendar Global Investor Relations Q3 2023 results October 2023 Phone: +49 2103 29 11457 Mobile: +49 152 018 11457 Q4 and FY 2023 results February 2024 E-mail: phoebe.loh@qiagen.com Share information Alexandra Koenig Coordinator NYSE: QGEN Investor Relations